References
1. World Health Organization. Coronavirus disease (COVID-19):
Situation Report–146[https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200614-covid-19-sitrep-146.pdf?sfvrsn=5b89bdad_4]
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu
N, et al: Genomic characterisation and epidemiology of 2019
novel coronavirus: implications for virus origins and receptor binding.Lancet (London, England) 2020, 395: 565-574.
3. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J,
Yip CC-Y, Poon RW-S, et al: A familial cluster of pneumonia
associated with the 2019 novel coronavirus indicating person-to-person
transmission: a study of a family cluster. Lancet (London,
England) 2020, 395: 514-523.
4. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau
EHY, Wong JY, et al: Early Transmission Dynamics in Wuhan,
China, of Novel Coronavirus–Infected Pneumonia. New England
Journal of Medicine 2020, 382: 1199-1207.
5. Barnes PJ: Targeting cytokines to treat asthma and chronic
obstructive pulmonary disease. Nature Reviews Immunology 2018,18: 454-466.
6. Rabe KF, Watz H: Chronic obstructive pulmonary disease.The Lancet 2017, 389: 1931-1940.
7. Papi A, Brightling C, Pedersen SE, Reddel HK: Asthma.The Lancet 2018, 391: 783-800.
8. Lambrecht BN, Hammad H, Fahy JV: The Cytokines of Asthma.Immunity 2019, 50: 975-991.
9. Kim V, Criner GJ: Chronic Bronchitis and Chronic Obstructive
Pulmonary Disease. American Journal of Respiratory and Critical
Care Medicine 2013, 187: 228-237.
10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu
X, et al: Clinical course and risk factors for mortality of
adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
study. The Lancet 2020, 395: 1054-1062.
11. Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, Huang H, Zhang L, Zhou X,
Du C, et al: Risk Factors Associated With Acute Respiratory
Distress Syndrome and Death in Patients With Coronavirus Disease 2019
Pneumonia in Wuhan, China. JAMA internal medicine 2020.
12. Wu Z, McGoogan JM: Characteristics of and Important Lessons
From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary
of a Report of 72 314 Cases From the Chinese Center for Disease Control
and Prevention. JAMA 2020, 323: 1239-1242.
13. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X, Cao B:SARS-CoV-2 and viral sepsis: observations and hypotheses.The Lancet 2020, 395: 1517-1520.
14. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M: The role of
peripheral blood eosinophil counts in COVID-19 patients. Allergy2020, n/a .
15. Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, Wei S, Deng Y, Liu
J, Liu H-G, et al: Analysis of factors associated with disease
outcomes in hospitalized patients with 2019 novel coronavirus disease.Chinese medical journal 2020, 133: 1032-1038.
16. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, Li C: The Clinical
and Chest CT Features Associated With Severe and Critical COVID-19
Pneumonia. Investigative radiology 2020, 55: 327-331.
17. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J: A
brief-review of the risk factors for covid-19 severity. Revista
de saude publica 2020, 54: 60.
18. Månsson A, Fransson M, Adner M, Benson M, Uddman R, Björnsson S,
Cardell LO: TLR3 in Human Eosinophils: Functional Effects and
Decreased Expression during Allergic Rhinitis. International
Archives of Allergy and Immunology 2010, 151: 118-128.
19. Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K,
Ohta K, Yamamoto K, Hirai K: Expression and Function of
Toll-Like Receptors in Eosinophils: Activation by Toll-Like Receptor 7
Ligand. The Journal of Immunology 2003, 171: 3977.
20. Wong CK, Cheung PFY, Ip WK, Lam CWK: Intracellular Signaling
Mechanisms Regulating Toll-Like Receptor–Mediated Activation of
Eosinophils. American Journal of Respiratory Cell and Molecular
Biology 2007, 37: 85-96.
21. Drake MG, Bivins-Smith ER, Proskocil BJ, Nie Z, Scott GD, Lee JJ,
Lee NA, Fryer AD, Jacoby DB: Human and Mouse Eosinophils Have
Antiviral Activity against Parainfluenza Virus. American Journal
of Respiratory Cell and Molecular Biology 2016, 55: 387-394.
22. Edwards MR, Strong K, Cameron A, Walton RP, Jackson DJ, Johnston SL:Viral infections in allergy and immunology: How allergic
inflammation influences viral infections and illness. Journal of
Allergy and Clinical Immunology 2017, 140: 909-920.
23. Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, Akdis CA,
Gao Y-d: Clinical characteristics of 140 patients infected with
SARS-CoV-2 in Wuhan, China. Allergy 2020, n/a .
24. Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran
P, Shen H, et al: Prevalence, risk factors, and management of
asthma in China: a national cross-sectional study. The Lancet2019, 394: 407-418.
25. Wang XD, Zheng M, Lou HF, Wang CS, Zhang Y, Bo MY, Ge SQ, Zhang N,
Zhang L, Bachert C: An increased prevalence of self-reported
allergic rhinitis in major Chinese cities from 2005 to 2011.Allergy 2016, 71: 1170-1180.
26. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang
Z, et al: Risk factors for severity and mortality in adult
COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical
Immunology 2020.
27. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P,
et al: Clinical Features of 85 Fatal Cases of COVID-19 from
Wuhan. A Retrospective Observational Study. American Journal of
Respiratory and Critical Care Medicine 2020, 201: 1372-1379.
28. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J:Patients of COVID-19 may benefit from sustained
Lopinavir-combined regimen and the increase of Eosinophil may predict
the outcome of COVID-19 progression. International Journal of
Infectious Diseases 2020, 95: 183-191.
29. Zhu C, Weng Q-Y, Zhou L-R, Cao C, Li F, Wu Y-F, Wu Y-P, Li M, Hu Y,
Shen J-X, et al: Homeostatic and Early Recruited CD101
Eosinophils Suppress Endotoxin-induced Acute Lung Injury. The
European respiratory journal 2020.
30. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA,
Visness CM, Durham SR, Larson D, Esnault S, et al: Association
of respiratory allergy, asthma, and expression of the SARS-CoV-2
receptor ACE2. Journal of Allergy and Clinical Immunology 2020,146: 203-206.e203.
31. Lindsley AW, Schwartz JT, Rothenberg ME: Eosinophil
responses during COVID-19 infections and coronavirus vaccination.Journal of Allergy and Clinical Immunology 2020.
32. Bass DA: Behavior of eosinophil leukocytes in acute
inflammation. II. Eosinophil dynamics during acute inflammation.The Journal of Clinical Investigation 1975, 56: 870-879.
33. Butterfield JH: Treatment of hypereosinophilic syndromes
with prednisone, hydroxyurea, and interferon. Immunology and
allergy clinics of North America 2007, 27: 493-518.
34. Hassani M, Leijte G, Bruse N, Kox M, Pickkers P, Vrisekoop N,
Koenderman L: Differentiation and activation of eosinophils in
the human bone marrow during experimental human endotoxemia.Journal of Leukocyte Biology 2020, n/a .
35. Faruqi S, Wilmot R, Wright C, Morice AH: Serum LDH in
chronic cough: a potential marker of airway inflammation. The
Clinical Respiratory Journal 2012, 6: 81-87.
36. Nillawar A, Bardapurkar J, Bardapurkar S: High sensitive
C-reactive protein as a systemic inflammatory marker and LDH-3 isoenzyme
in chronic obstructive pulmonary disease. Lung India 2012,29: 24-29.
37. Loppow D, Schleiss MB, Kanniess F, Taube C, JÖRres RA, Magnussen H:In patients with chronic bronchitis a four week trial with
inhaled steroids does not attenuate airway inflammation.Respiratory Medicine 2001, 95: 115-121.
38. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y,
Liu S, et al: Risk factors of critical & mortal COVID-19 cases:
A systematic literature review and meta-analysis. Journal of
Infection 2020.
39. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu
X, et al: Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet (London, England) 2020,395: 497-506.
40. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,
Xiong Y, et al: Clinical Characteristics of 138 Hospitalized
Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
China. JAMA 2020, 323: 1061-1069.
41. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y,
Wei Y, et al: Epidemiological and clinical characteristics of 99
cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
study. Lancet (London, England) 2020, 395: 507-513.
42. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu
H, Zhu L, et al: Pathological findings of COVID-19 associated
with acute respiratory distress syndrome. The Lancet Respiratory
Medicine 2020, 8: 420-422.
43. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY,
Leung CB, To KF, et al: A Major Outbreak of Severe Acute
Respiratory Syndrome in Hong Kong. New England Journal of
Medicine 2003, 348: 1986-1994.
44. Hong K-H, Choi J-P, Hong S-H, Lee J, Kwon J-S, Kim S-M, Park SY,
Rhee J-Y, Kim B-N, Choi HJ, et al: Predictors of mortality in
Middle East respiratory syndrome (MERS). Thorax 2018,73: 286.
45. Peiris JSM, Yuen KY, Osterhaus ADME, Stöhr K: The Severe
Acute Respiratory Syndrome. New England Journal of Medicine2003, 349: 2431-2441.
46. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H,
Lei C-l, Hui DSC, et al: Clinical Characteristics of Coronavirus
Disease 2019 in China. New England Journal of Medicine 2020,382: 1708-1720.
47. Marshall JC, Charbonney E, Gonzalez PD: The Immune System in
Critical Illness. Clinics in Chest Medicine 2008,29: 605-616.
48. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang
X, Yan X, et al: The use of anti-inflammatory drugs in the
treatment of people with severe coronavirus disease 2019 (COVID-19): The
Perspectives of clinical immunologists from China. Clinical
immunology (Orlando, Fla) 2020, 214: 108393.
49. Sheng W-H, Chiang B-L, Chang S-C, Ho H-N, Wang J-T, Chen Y-C, Hsiao
C-H, Hseuh P-R, Chie W-C, Yang P-C: Clinical manifestations and
inflammatory cytokine responses in patients with severe acute
respiratory syndrome. Journal of the Formosan Medical Association
= Taiwan yi zhi 2005, 104: 715-723.
50. Zhu M: SARS Immunity and Vaccination. Cellular &
molecular immunology 2004, 1: 193-198.
51. Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, Lit LCW, Hui
DSC, Chan MHM, Chung SSC, Sung JJY: Plasma inflammatory
cytokines and chemokines in severe acute respiratory syndrome.Clinical & Experimental Immunology 2004, 136: 95-103.
52. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA:MERS-CoV infection in humans is associated with a
pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 2018,104: 8-13.
53. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J: Tocilizumab
treatment in COVID-19: A single center experience. Journal of
Medical Virology 2020, 92: 814-818.
54. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ:COVID-19: consider cytokine storm syndromes and
immunosuppression. The Lancet 2020, 395: 1033-1034.
55. Ruan Q, Yang K, Wang W, Jiang L, Song J: Clinical predictors
of mortality due to COVID-19 based on an analysis of data of 150
patients from Wuhan, China. Intensive care medicine 2020,46: 846-848.
56. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q: Cytokine release
syndrome in severe COVID-19: interleukin-6 receptor antagonist
tocilizumab may be the key to reduce mortality. International
Journal of Antimicrobial Agents 2020, 55: 105954.
57. World Health Organization. Clinical management of severe
acute respiratory infection when novel coronavirus (2019-nCoV) infection
is suspected: interim guidance[https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf]